Blog
Posts Categorized: Acasti Pharma
-
Acasti Pharma – Peer success shows investors could make a krilling
It’s been a good ride for investors in Nasdaq listed krill oil specialist Acasti Pharmaceuticals (ACST) since we published our LATEST ANALYSIS on Monday this week. Trading at 1.29 cents at the time of our article, the shares rose to a peak of 2.25 cents before settling to the current level of 1.56 cents. That […]
-
Acasti Pharmaceuticals – market begins to wake up to the explosive upside on offer should CaPre Phase 3 trials prove successful
By Richard Jennings It has been a slow burn for followers of us into Nasdaq listed Acasti Pharmaceuticals (ACST) as per our original article per HERE but we believe that the stock is now primed to move decisively ahead as the company moves up the most important stage of the pharma sector“value proving” curve – […]
-
Zak Mir interviews Richard Jennings, CEO, Align Research
Zak Mir interviews Richard Jennings, CEO, Align Research, discussing the on goings of the past year and the outlook for 2018. https://zakmir.files.wordpress.com/2017/12/align.m4a Key points discussed Addressing twitter/bulletin board “trolls” Elaboration on some of the top 10 picks for 2018 Global markets outlook Business model background
-
Align Research’s Top 10 Conviction Picks for 2018
Well, it’s that time of year again where we look ahead to the new calendar year and place our “cooking” and conviction picks at Align on show for 2018. Last year’s picks are HERE and we are pleased to relay we had some real winners. ZIOC was the stand out performer – rising from 6.5p […]
-
Acasti Pharma – A View to a Krill
Made in the liver and found in some foods, cholesterol is a fatty substance, carried in the blood attached to proteins called lipoproteins, which is vital for the normal functioning of the human body. However, having an excessively high level of cholesterol in the blood can increase the risk of developing serious health conditions. Over […]